Cytokinetics Inc. priced its initial public offering Thursday, raising $89.7 million, slightly more than it expected to raise when it filed in January. (BioWorld Today)

Exceeding consensus estimates, Amgen Inc.'s first-quarter results showed strong sales that analysts said leave the company poised for near-term growth. (BioWorld Today)

Transforming itself from a development company to one that has its own sales force, BioMarin Pharmaceutical Inc. signed definitive plans to acquire Ascent Pediatrics Inc. for $175 million in cash and stock payments over five years. (BioWorld Today)

In its largest financing to date, Dynogen Pharmaceuticals Inc. secured $50 million in a Series B round, enabling it to build its pipeline and advance its two clinical compounds. (BioWorld Today)